iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Lupin enters in partnership agreement with China's Foncoo Pharma for high-quality and complex generic medicines

19 Jan 2022 , 11:54 AM

Lupin Ltd on Wednesday announced its partnership with Shenzhen Foncoo Pharmaceutical Co. Ltd. which reinforces its commitment to bringing high-quality generic and complex generic medicines to patients around the world. This partnership is in arrangement with China and enforces Lupin’s commitment to bring high-quality generic and complex generic medicines to patients around the world.

“Lupin continues to invest in key growth markets. With China’s growing dedication to affordable and accessible healthcare for all, Lupin is dedicated to serving the healthcare needs of the Chinese population by bringing forth high quality generic and complex generic products,” said Dr. Fabrice Egros, President — Growth Markets, Lupin.

He further added, “We are thrilled about our partnership with Foncoo and seek to further explore additional partnership opportunities in China to leverage our global portfolio including complex generics and specialty medicines.”

“Foncoo’s successful experiences on importing registration and marketing of the generic formulations and Lupin’s strong capability of making high-quality medicines make us perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon. We will continue to explore further opportunities to work with Lupin for providing more and more high-value and complex medicines to the Chinese physicians and patients,” said General Manager, Mr. Peng Yan, Foncoo.

Lupin enjoys leader position in the cardiovascular, respiratory segments and anti-diabetic, and has a significant presence in the anti-infective, gastro-intestinal (GI), women’s health, and central nervous system (CNS) areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions.

Related Tags

  • Lupin News
  • Lupin Partnership
  • Lupin Stock
  • Lupin Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
19 Mar 2024   |   10:37 AM
Images
18 Mar 2024   |   11:30 AM
Images
18 Mar 2024   |   10:42 AM
Images
18 Mar 2024   |   10:36 AM
Read More

Most Read News

19 Mar 2024   |   02:16 PM
19 Mar 2024   |   02:11 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.